ID: ALA427320

Max Phase: Preclinical

Molecular Formula: C13H8BrNO4S2

Molecular Weight: 386.25

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)c1sccc1S(=O)(=O)n1ccc2cc(Br)ccc21

Standard InChI:  InChI=1S/C13H8BrNO4S2/c14-9-1-2-10-8(7-9)3-5-15(10)21(18,19)11-4-6-20-12(11)13(16)17/h1-7H,(H,16,17)

Standard InChI Key:  ZYGWKDDRPATRQB-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 386.25

Molecular Weight (Monoisotopic): 384.9078

AlogP: 3.40

#Rotatable Bonds: 3

Polar Surface Area: 76.37

Molecular Species: ACID

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.05

CX Basic pKa:

CX LogP: 3.34

CX LogD: -0.13

Aromatic Rings: 3

Heavy Atoms: 21

QED Weighted: 0.75

Np Likeness Score: -1.63

References

1. Lehmann F, Haile S, Axen E, Medina C, Uppenberg J, Svensson S, Lundbäck T, Rondahl L, Barf T..  (2004)  Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target.,  14  (17): [PMID:15357969] [10.1016/j.bmcl.2004.06.057]

2. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of MMV (CH) - Pandemic Response Box,  [10.6019/CHEMBL4513161]

3. Floresta G, Pistarà V, Amata E, Dichiara M, Marrazzo A, Prezzavento O, Rescifina A..  (2017)  Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review.,  138  [PMID:28738306] [10.1016/j.ejmech.2017.07.022]

Source

Source(2):

• Scientific Literature
• CO-ADD antimicrobial screening data